Rain Enhancement Technologies Holdco, Inc. (RAIN) Q3 2022 Earnings Call

Investor webinar replay

Replay transcript excerpt

Greetings and welcome to the RAIN Therapeutics Third Quarter Earnings Conference Call. At this time, all participants are in a listen-only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Dan Ferry with LifeSci Advisors. Please go ahead. Thank you, Operator. and good afternoon. With me today on the phone are Avinish Valanki, Chief Executive Officer of RAIN Therapeutics, Robert Doble, Chief Scientific Officer, Richard Bryce, Chief Medical Officer, and Nelson Cabotuan, SVP of Finance. During today's call, Avinish will provide an overall business update. Bob will review the interim Mantra 2 data. Richard will provide an update on RAIN's clinical programs. and Nelson will review the financials. Before we begin, I would like to remind you that statements made during this conference call that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon RAIN's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties as described in RAIN's annual report on Form 10-K for the year ended December 31st, 2021 and subsequent filings with the Securities and Exchange Commission. All forward-looking statements made during this conference call are based on management's assumptions and estimates as of today, November 10th, 2022. RAIN undertakes ...